Literature DB >> 18292396

Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis.

Céline Bouvet1, Simon Moreau, Joannie Blanchette, Denis de Blois, Pierre Moreau.   

Abstract

OBJECTIVE: Isolated systolic hypertension is associated with increased elastase activity, vascular calcification, and vascular stiffness. We sought to determine the importance of elastase activity and matrix degradation in the development of elastocalcinosis. METHODS AND
RESULTS: Elastocalcinosis was induced in vivo and ex vivo using warfarin. Hemodynamic parameters, calcium deposition, elastin degradation, transforming growth factor (TGF)-beta signaling, and elastase activity were evaluated at different time points in the in vivo model. Metalloproteinases, serine proteases, and cysteine proteases were blocked to measure their relative implication in elastin degradation. Gradual elastocalcinosis was obtained, and paralleled the elastin degradation pattern. Matrix metalloproteinase (MMP)-9 activity was increased at 5 days of warfarin treatment, whereas TGF-beta signaling was increased at 7 days. Calcification was significantly elevated after 21 days. Blocking metalloproteinases activation with doxycycline and TGF-beta signaling with SB-431542 were able to prevent calcification.
CONCLUSIONS: Early MMP-9 activation precedes the increase of TGF-beta signaling, and overt vascular elastocalcinosis and stiffness. Modulation of matrix degradation could represent a novel therapeutic avenue to prevent the gradual age-related stiffening of large arteries, leading to isolated systolic hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292396     DOI: 10.1161/ATVBAHA.107.153056

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  29 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

2.  Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease.

Authors:  Ashwini Pai; Elizabeth M Leaf; Mohga El-Abbadi; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  Arterial calcification in chronic kidney disease: key roles for calcium and phosphate.

Authors:  Catherine M Shanahan; Matthew H Crouthamel; Alexander Kapustin; Cecilia M Giachelli
Journal:  Circ Res       Date:  2011-09-02       Impact factor: 17.367

4.  Genetic interleukin-10 deficiency causes vascular remodeling via the upregulation of Nox1.

Authors:  Jagadeesha K Dammanahalli; Xiuqing Wang; Zhongjie Sun
Journal:  J Hypertens       Date:  2011-11       Impact factor: 4.844

Review 5.  Chronic kidney disease as a coronary artery disease risk equivalent.

Authors:  Alexandrios Briasoulis; George L Bakris
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

Review 6.  Vascular calcification: pathophysiology and risk factors.

Authors:  Neal X Chen; Sharon M Moe
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

7.  Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification.

Authors:  Kelly E Beazley; Stephanie Deasey; Florence Lima; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

Review 8.  Elastin in large artery stiffness and hypertension.

Authors:  Jessica E Wagenseil; Robert P Mecham
Journal:  J Cardiovasc Transl Res       Date:  2012-06       Impact factor: 4.132

Review 9.  Skin manifestations in CDG.

Authors:  D Rymen; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2014-02-20       Impact factor: 4.982

10.  Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study.

Authors:  Pawel Szulc; Elizabeth J Samelson; Douglas P Kiel; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.